Haemonetics Corporation provided revenue guidance for the fiscal year 2025. For the year, the company expects GAAP total reported revenue growth to be between 5% to 8%, and total organic revenue growth to be between 0% to 3%.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
86.34 USD | +0.98% | +2.04% | +1.03% |
Jun. 12 | Haemonetics Shares Rise After Upgrade From Needham | MT |
Jun. 12 | Needham Upgrades Haemonetics to Buy From Hold, Sets Price Target at $112 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.03% | 4.36B | |
-4.24% | 185B | |
-2.09% | 105B | |
-2.51% | 68.9B | |
+15.27% | 46.41B | |
-7.29% | 46.16B | |
+5.36% | 40.75B | |
+19.99% | 31.11B | |
+11.60% | 24.26B | |
-6.09% | 23.94B |
- Stock Market
- Equities
- HAE Stock
- News Haemonetics Corporation
- Haemonetics Corporation Provides Revenue Guidance for the Fiscal Year 2025